LAPTM5 and neuroblastoma: These regressing areas with LAPTM5-positive degenerating NB cells were much more frequently observed in the mass-screened NB tumors (42 of 54 tumors, 77.8%), than in the clinically detected NB tumors (1 of 17 tumors, 5.9%) (Figure 2B).